Clicky

Sarepta Therapeutics, Inc.(SRPT)

Description: Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is eteplirsen, an antisense PMO-based therapeutic, which is in Phase IIb clinical development for the treatment of individuals with Duchenne muscular dystrophy. The company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.


Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Infectious Diseases Rare Diseases Clinical Development Influenza Clinical Research Dystrophy Muscular Dystrophy Duchenne Muscular Dystrophy Therapeutic Gene Modulation Duchenne Antisense Therapy Antisense RNA Sarepta Therapeutics

Home Page: www.sarepta.com

SRPT Technical Analysis

215 First Street
Cambridge, MA 02142
United States
Phone: 617 274 4000


Officers

Name Title
Mr. Douglas S. Ingram Esq. Pres, CEO & Director
Mr. Ian Michael Estepan Exec. VP & CFO
Mr. William F. Ciambrone Exec. VP of Technical Operations
Dr. Louise R. Rodino-Klapac Ph.D. Exec. VP, Chief Scientific Officer and Head of R&D
Mr. Ryan E. Brown Sr. VP, Gen. Counsel & Corp. Sec.
Bilal Arif Sr. VP of Strategy and Operations
Mary Jenkins Sr. Mang. of Investor Relations
Ms. Alison Nasisi Chief People Officer & VP
Dr. Diane L. Berry Sr. VP of Global Health Policy and Gov. & Patient Affairs
Mr. Dallan Murray Sr. VP & Chief Customer Officer

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 25.7374
Price-to-Sales TTM: 12.4903
IPO Date: 1997-06-03
Fiscal Year End: December
Full Time Employees: 840
Back to stocks